Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: No
View:

• Patient over the age of 21

• Bladder tumor suspected or confirmed

• ECOG status 0 to 2

• Premedication Lab values:

• Absolute Neutrophil Count >750 cells/m3 AST/ALT less than 1.5xN Amylase less than 1.5xN Platelet Count > 125,000 PT/PTT > 1.3xN Hemoglobin > 8gm/dL Creatinine less than 1.5xN

Locations
United States
New York
SUNY Upstate Medical University
Syracuse
Time Frame
Start Date: December 2011
Completion Date: April 2014
Participants
Target number of participants: 43
Treatments
Experimental: valproic acid
Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
Authors
Related Therapeutic Areas
Sponsors
Leads: State University of New York - Upstate Medical University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials